Filter

Corporate NewsDrug DiscoveryIndustry NewsPress ReleasePress Release

BioSymetrics Collaborates with Janssen and Sema4 to Predict the Onset of COVID-19

August 19, 2020
As part of the collaboration, the parties will use BioSymetrics’ Contingent-AI™ engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease.
Uncategorized

Drug Repurposing Prediction Using AI and SARS-CoV-2 High-Content Imaging Screening Data

August 18, 2020
We were recently approached by a clinical-stage biotech client to investigate one of their lead compounds used to treat COPD. Specifically, we wanted to know whether this compound would have any activity against SARS-CoV-2.
Corporate NewsDrug DiscoveryPress Release

BioSymetrics Joins Accenture’s INTIENT Network

August 13, 2020
"BioSymetrics’ participation in the ecosystem and integration with Accenture's INTIENT network will give scientists another important capability to help interpret the growing volumes of rich and diverse data that is being generated in drug discovery.”
Blog PostDrug Discovery

Explore Drug Effects Against SARS-CoV-2 Phenotypic Screening in the Interactive Blog

June 23, 2020
Remdesivir shows strong, dose-dependent therapeutic effects against SARS-CoV-2 in phenotypic screening. Our interactive COVID-19 blog lets you explore the data.
Case StudyDrug DiscoveryMediaVideo

Predicting Mechanism of Action Using AI – Webinar

June 16, 2020
In this webinar, Mikalai Malinouski Ph.D.demonstrated how BioSymetrics uses AI in the prediction of mechanism of action (MOA), and provided a an example of how machine learning workflows can benefit both novel drug discovery and drug repositioning.
Case StudyDrug Discovery

Poster Presentation: MIT 2020 AI for Drug Discovery Conference

May 11, 2020
Both target and phenotype driven drug discovery strategies rely on identifying relationships between specific drugs and targets of interest. In this poster we present our automated way to integrate diverse data sets and develop machine learning models against specific protein targets.
Drug DiscoveryIndustry News

Uniting Against COVID-19

March 30, 2020
Already working with clinicians, leveraging international collaborations to put prediction platforms in place, and re-investigating our drug lead pipeline, BioSymetrics will pursue any collaboration to have a positive impact against COVID and support the heroes working tirelessly in the hospitals and clinics around the world.
Blog PostCase StudyDrug Discovery

Mitigating Batch Effects in Cell Painting Data

March 23, 2020
With the advent of high content screening methodologies (e.g. cellular imaging, transcriptomics, etc.), it becomes more challenging to tease apart and visualize batch effects. This is further compounded when building machine learning models which can easily use these confounding variables instead of real biological signal to generate predictions leading to poor real world relevance.
Blog PostCase StudyDrug Discovery

De-noising CMap L1000 Data

February 12, 2020
As with any assay, L1000 data is noisy. Experimental replicates (the same compound tested on the same cell line under the same conditions) often result in different levels of expression being measured. The process of de-noising the L1000 data makes it easier to see true assay response, and pick a representative concentration for each compound.
Blog PostCase StudyDrug Discovery

When are Two Compounds the Same?

January 28, 2020
When are two compounds the same? The effect of Simplified Molecular Input Line Entry System (SMILES) format on chemical database overlap including best practice for canonicalization and harmonization to understand the impact of these compound effects on a particular dataset and specific application.
Blog PostCase StudyDrug Discovery

Dealing with Missing Values in Healthcare Data

January 21, 2020
In this post, we highlight the challenges of missing values when modelling with time-series data of EMRs and discuss some techniques to address it.
Case StudyDrug Discovery

Phenotype/Mechanism Prediction

January 10, 2020
Use Case: BioSymetrics ML framework generates structure-based activity predictions using phenotypic assays and HCS data to identify protein targets and affected pathways
Case StudyDrug Discovery

Bias Reduction in HCS Data

January 3, 2020
Bias Reduction in High Content Screening can be solved using BioSymetrics Augusta™ machine learning platform.
MediaPodcast

The Business of Healthcare Podcast

November 14, 2019
Anthony Iacovone, Chairman of BioSymetrics, joins host Dr. Bob Kaiser for a discussion about what biomedical artificial intelligence and machine learning are and how they can be used to improve outcomes in the areas of drug discovery, clinical diagnostics and value-based care as well as reduce healthcare costs.
Augusta™Blog PostCase Study

Feature Engineering of Electronic Medical Records

October 2, 2019
A comprehensive overview of data cleaning and feature engineering techniques for clinical data
Corporate NewsEvent

AI in Pharma Summit, Boston Oct-9

September 25, 2019
Gabe Musso, Chief Science Offer will be speaking at the AI in Pharma summit in Boston on October 9th.  His unique perspective on data management in drug discovery and clinical trials will try to wrestle with the timeless question on how to manage and process fragmented data. 
Podcast

Podcast: ‘Talking Precision Medicine’ with Gabe Musso

September 17, 2019
Gabe Muso, Chief Science Officer, BioSymetrics speaks with Rafael Rosengarten CEO of Genialis on the practice of improving data preprocessing for the advancement of machine learning in medicine.
Blog Post

Dishing Dirt About Clean Data

June 20, 2019
A daughter's desire to please her parents demonstrates how a data scientist with good intentions can cause far more harm and expense in the long run, through the selection and creation of the wrong features during data pre-processing.
Event

AI-PI Conference

January 7, 2019